David van Veenhuyzen

David van Veenhuyzen has a diverse and extensive work experience in the pharmaceutical and biotech industry. David is currently serving as the Vice President of Clinical Development at Navire Pharma, a BridgeBio company, where they lead and oversees the Clinical Development, Clinical Operations, Pharmacovigilance, and Biostatistics teams. David reports directly to the Chief Scientific Officer (CSO) and is responsible for building high-performing teams and providing oversight of clinical programs.

In addition, David has also held the role of Vice President of Clinical Development at QED Therapeutics, Inc., another BridgeBio company. Here, they headed the Clinical Development, Pharmacovigilance, and Medical Affairs departments.

Prior to their current roles, David founded and served as the Principal Consultant of their own company, Van Veenhuyzen, Clinical Research Consulting LLC, where they provided consulting services to pharmaceutical and biotech industries. David'sservices included clinical development lead, study medical lead, medical monitor, and drug safety physician roles. Some of their clients included Mirum, BridgeBio, Ardeagen, Spannerwerks, PharmaIN, and Catalyst Clinical Research.

David has also worked at Myovant Sciences as the Senior Medical Director of Clinical Development, where they led the clinical strategy and oversight for the Advanced Prostate Cancer and Endometriosis programs. David played a key role in obtaining FDA approval for Relugolix 120 mg as Orgovyx for the treatment of advanced prostate cancer.

Before that, David worked as the Senior Medical Director at Aquinox Pharmaceuticals, Inc., where they led the Drug Safety, Medical Affairs, and Clinical Development Physicians teams. David was actively involved in the clinical development of rosiptor for the treatment of interstitial cystitis/bladder pain syndrome.

David has also worked as a Pharmaceutical Consultant to Aquinox Pharmaceuticals, Inc. and as the Head of Late Stage Clinical Development and Global Clinical Development Lead for cefiderocol at Shionogi Inc.

David'scareer also includes significant experience at Bayer, where they held various positions such as Global Clinical Leader across multiple therapeutic areas, including anti-infectives, hematology, and cardiovascular. David also served as the Head of Medical and Regulatory Affairs, Southern and Eastern Africa, at Bayer Pty Ltd, where they led a team and made substantial contributions to pivotal global clinical studies.

David's work experience spans over two decades, and they have proven expertise in clinical development, pharmacovigilance, medical affairs, and drug safety.

David van Veenhuyzen obtained their first degree, a Bachelor of Medicine and Bachelor of Chirurgery (M.B., Ch.B.), from the University of Pretoria/Universiteit van Pretoria in 1989. David then pursued further education at the same institution, earning a Master of Pharmacy in Medicine (M.Pharm.Med) with a specialization in Pharmacology, which they completed in 1996.